Stay updated with breaking news from Milton Werner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Greetings and welcome to Inhibikase Therapeutics First Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Meeting to discuss potential of IkT-001Pro as a disease modifying treatment for Pulmonary Arterial HypertensionBOSTON and ATLANTA, April 03, 2024 -- Inhibikase Therapeutics, Inc. , a...
Inhibikase Therapeutics, Inc. (IKT) announced it will meet with the Office of Cardiology, Hematology, Endocrinology and Nephrology in the Division of Cardiology and Nephrology at the FDA for a Pre-IND meeting to discuss IkT-001Pro as a treatment for Pulmonary Arterial Hypertension.
- The Company continues to progress the 201 Trial evaluating risvodetinib in untreated Parkinson’s disease -BOSTON and ATLANTA, Feb. 07, 2024 -- Inhibikase Therapeutics, Inc. , a...
Data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volunteers or worsening of symptoms in participants taking anti-PD...